Trial Profile
An Open-Label, Long-Term Safety Study Including a Double-Blind, Placebo-Controlled, Randomized Withdrawal Period of TEV-50717 (Deutetrabenazine) for the Treatment of Tourette Syndrome in Children and Adolescents
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 19 May 2022
Price :
$35
*
At a glance
- Drugs Deutetrabenazine (Primary)
- Indications Gilles de la Tourette's syndrome
- Focus Adverse reactions; Registrational
- Acronyms ARTISTS
- Sponsors Teva Branded Pharmaceutical Products R&D
- 18 Dec 2021 This trial has been completed in Poland, according to European Clinical Trials Database record.
- 05 Jul 2020 This trial has been completed in Hungary, according to European Clinical Trials Database record.
- 23 Jun 2020 Status changed from active, no longer recruiting to discontinued.